PERSONAL
PROFESSIONAL
PHILANTHROPY
CONTACT
Home
>>
Professional Posts
Pete Petit's Professional Posts
2017
MiMedx CEO Pete Petit turns eye treatment into a $320M sterile wound care go-to
Pursuit and Passion Drives MiMedx CEO Pete Petit
MiMedx lands in Fortune’s Top 100 growing companies list
Multicenter Randomized Controlled VLU Clinical Study Published in the International Wound Journal Demonstrates Significantly Higher Healing Rates of MiMedx EpiFix®
MiMedx Announces Third Quarter Revenues Of $84.6 Million Exceeds Guidance By More Than 5 Percent
MiMedx Adds New Materials To Its Website Exposing Misinformation Disseminated Through Short Seller Attacks
MiMedx Board of Directors Authorizes $10 Million Increase to the Company's Share Repurchase Program
MiMedx Files Lawsuit Related To Short Seller Attacks
Dr. Gloria Matthews Joins MiMedx As Its Senior Vice President Of Research And Development
Court Sets the Trial Date for MiMedx Patent Infringement Lawsuit Against MTF, Medline and Liventa
MiMedx Completes Divestiture Of Its Stability Biologics Subsidiary
MiMedx Publishes Document on its Website Exposing False and Misleading Information Distributed By Viceroy Research and Aurelius Value
MiMedx Agrees To Lawsuit Settlement With Terminated Employee
MiMedx Files Lawsuit Against The Capitol Forum
MiMedx provides Information on Its Interaction With The SEC
MiMedx Responds To Deceptive Short Seller Reports
MiMedx To Host Shareholder Call On September 21, 2017 To Update Progress On Various Strategic Initiatives And Respond To Topics Requested By Shareholders
MiMedx Files With The FDA To Initiate The Company's Investigational New Drug Phase 2 Clinical Trial For Osteoarthritis Of The Knee
MiMedx Patent Infringement Lawsuit Updates
MiMedx Reiterates Its Third Quarter Revenue Expectation To Exceed $80 Million Despite Hurricane Irma
MiMedx Recognized as Number 5 on Fortune Magazine's List of the 100 Fastest Growing Public Companies
MiMedx Notified By FDA That It Can Proceed With Phase 3 Investigational New Drug Clinical Trial For Achilles Tendonitis
MiMedx Reports Further Developments in its Civil Litigation Against Former Employees
MiMedx Announces Its Expectations For Third Quarter Revenue To Exceed $80 Million And Surpass Its Previous Revenue Guidance
MiMedx Reports MultiCenter randomized Controlled VLU Clinical Study Accepted for Publication in The International Wound Journal
MiMedx Signs Definitive Agreement to Divest Stability Biologics Subsidiary as Part of Company's Strategic Focus on Biopharma
MiMedx Provides Update on Litigation with Terminated Employees
MiMedx Hits Milestone of One Million Allografts Distributed
MiMedx Files With The FDA To Initiate Its Investigational New Drug Achilles Tendonitis Phase 3 Clinical Trial
MiMedx Reports Exceptional Results in Phase 2B Clinical Trial on the Use of AmnioFix® Injectable in the Treatment of Plantar Fasciitis
MiMedx Initiates Phase 3 Plantar Fasciitis Clinical Trial
MiMedx Announces Record Results For The Second Quarter Of 2017 And Raises Full Year Revenue Guidance
MiMedx Announces That Its Second Quarter Revenue Exceeds The Guidance Range
MiMedx Agreement With AvKARE Expires As Planned Following Completion Of Contract Wind-Down
Scientific And Clinical Review Confirms Potential Of MiMedx dHACM Allografts For Regenerative Applications In Orthopedics
MiMedx Amniofix® data showing colorectal anastomotic leak rate reduction presented at ASCRS Meeting
MiMedx Receives Innovative Technology Supplier of the Year Award from Vizient, Inc.
MiMedx Announces Record Results For First Quarter Of 2017
MiMedx Announces First Quarter 2017 Revenue to Exceed High End of Guidance
The Use Of MiMedx Allografts From The Company's Multiple Product Families To Be Presented At SAWC Conference
MiMedx Announces The Addition Of Luis A. Aguilar To Its Board Of Directors
MiMedx to Host Shareholder call on March 9, 2017 to present various strategic and tactical initiatives to shareholders
MiMedx Audit Committee Announces Completion Of Its Investigation
MiMedx Announces 2016 Record Results
MiMedx Announces Release Date for 2016 Full Year Results
Benefits Of MiMedx dHACM Allograft Chronicled In Multiple Articles In February 2017 Supplement Edition Of Annals of Plastic Surgery
MiMedx Board of Directors Authorizes $10 Million Increase to the Company's Share Repurchase Program
MiMedx Comments On FDA Decision Not To Finalize HCT/P Guidance Documents This Year
Scientific Study Confirms MiMedx dHACM Allograft Promotes Cardiac Repair Following Myocardial Infarction
MiMedx Fourth Quarter 2016 Revenue in Upper Range of Guidance